Beyond lipodystrophy: will toxicity issues ever outweigh the benefits of HAART?

J HIV Ther. 2003 May;8(2):27-8.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Adverse Drug Reaction Reporting Systems
  • Anti-HIV Agents / adverse effects*
  • Anti-HIV Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active / adverse effects*
  • Female
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • HIV-Associated Lipodystrophy Syndrome / chemically induced*
  • HIV-Associated Lipodystrophy Syndrome / virology
  • Humans
  • Male
  • Myocardial Infarction / chemically induced
  • Pregnancy
  • Sex Factors
  • Smoking

Substances

  • Anti-HIV Agents